Tecentriq is a cancer immunotherapy designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells. By inhibiting PD-L1, Tecentriq may enable the activation of T cells. Tecentriq is approved in countries around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various forms of non-small cell lung cancer (NSCLC), as well as certain types of small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), metastatic urothelial cancer (UC), PD-L1-positive metastatic triple-negative breast cancer (TNBC), BRAF V600 mutation-positive advanced melanoma and alveolar soft part sarcoma (ASPS).
Tecentriq is the first PD-(L)1 cancer immunotherapy which can be administered intravenously (into a vein) and subcutaneously (under the skin).
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.